Sequent Scientific Limited — Investor Meet, 29-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

SeQuent Scientific reported Q4 revenues of INR401.7 Cr, up 11.2% YoY, led by 22% growth in formulations and a 7% QoQ rise in APIs. EBITDA pre-ESOP rose 38.7% YoY to INR56.9 Cr with 14.2% margins. FY25 revenue grew 13.3% to INR1,551.6 Cr; PAT turned positive at INR32.2 Cr. Viyash Life Sciences posted Q4 revenue of INR370 Cr (+15%), with EBITDA nearly doubling to INR65.3 Cr at 17.6% margins. FY25 EBITDA expanded 52.4% to INR254.6 Cr. The merger is advancing toward closure by FY26-end, with synergy benefits expected. Growth drivers include new product launches, geographic expansion, improved mix favoring high-margin companion animal and CDMO segments, and operational efficiencies. Management is confident of mid-teens revenue growth and margin expansion toward ~20% EBITDA for the combined entity over 2-3 years. Cash flow and debt metrics are improving, with Viyash targeting debt-free status in FY26.